155 related articles for article (PubMed ID: 1414239)
1. Oxiracetam in dementia: a double-blind, placebo-controlled study.
Bottini G; Vallar G; Cappa S; Monza GC; Scarpini E; Baron P; Cheldi A; Scarlato G
Acta Neurol Scand; 1992 Sep; 86(3):237-41. PubMed ID: 1414239
[TBL] [Abstract][Full Text] [Related]
2. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.
Maina G; Fiori L; Torta R; Fagiani MB; Ravizza L; Bonavita E; Ghiazza B; Teruzzi F; Zagnoni PG; Ferrario E
Neuropsychobiology; 1989; 21(3):141-5. PubMed ID: 2693996
[TBL] [Abstract][Full Text] [Related]
3. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree.
Villardita C; Grioli S; Lomeo C; Cattaneo C; Parini J
Neuropsychobiology; 1992; 25(1):24-8. PubMed ID: 1603291
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group.
Parnetti L; Mecocci P; Petrini A; Longo A; Buccolieri A; Senin U
Neuropsychobiology; 1989; 22(2):97-100. PubMed ID: 2518332
[TBL] [Abstract][Full Text] [Related]
5. Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia.
Dysken MW; Katz R; Stallone F; Kuskowski M
J Neuropsychiatry Clin Neurosci; 1989; 1(3):249-52. PubMed ID: 2521069
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.
Rozzini R; Zanetti O; Bianchetti A
Acta Neurol (Napoli); 1992 Apr; 14(2):117-26. PubMed ID: 1414555
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.
Rozzini R; Zanetti O; Bianchetti A
Acta Neurol (Napoli); 1993 Feb; 15(1):44-52. PubMed ID: 8456595
[TBL] [Abstract][Full Text] [Related]
8. Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia.
Chibnall JT; Tait RC; Harman B; Luebbert RA
J Am Geriatr Soc; 2005 Nov; 53(11):1921-9. PubMed ID: 16274373
[TBL] [Abstract][Full Text] [Related]
9. Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study.
Moglia A; Sinforiani E; Zandrini C; Gualtieri S; Corsico R; Arrigo A
Clin Neuropharmacol; 1986; 9 Suppl 3():S73-8. PubMed ID: 3594459
[TBL] [Abstract][Full Text] [Related]
10. Oxiracetam in the treatment of multi-infarct dementia.
Baumel B; Eisner L; Karukin M; MacNamara R; Katz RJ; Deveaugh-Geiss J
Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(5):673-82. PubMed ID: 2781039
[TBL] [Abstract][Full Text] [Related]
11. Selegiline versus oxiracetam in patients with Alzheimer-type dementia.
Falsaperla A; Monici Preti PA; Oliani C
Clin Ther; 1990; 12(5):376-84. PubMed ID: 2125242
[TBL] [Abstract][Full Text] [Related]
12. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia.
Pantoni L; Bianchi C; Beneke M; Inzitari D; Wallin A; Erkinjuntti T
J Neurol Sci; 2000 Apr; 175(2):116-23. PubMed ID: 10831772
[TBL] [Abstract][Full Text] [Related]
13. Treatment trial of oxiracetam in Alzheimer's disease.
Green RC; Goldstein FC; Auchus AP; Presley R; Clark WS; Van Tuyl L; Green J; Hersch SM; Karp HR
Arch Neurol; 1992 Nov; 49(11):1135-6. PubMed ID: 1444879
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute doses of oxiracetam in the scopolamine model of human amnesia.
Preda L; Alberoni M; Bressi S; Cattaneo C; Parini J; Canal N; Franceschi M
Psychopharmacology (Berl); 1993; 110(4):421-6. PubMed ID: 7870912
[TBL] [Abstract][Full Text] [Related]
15. Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.
Villardita C; Parini J; Grioli S; Quattropani M; Lomeo C; Scapagnini U
J Neural Transm Suppl; 1987; 24():293-8. PubMed ID: 3479527
[TBL] [Abstract][Full Text] [Related]
16. Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy.
Aldenkamp AP; van Wieringen A; Alpherts WC; van Emde Boas W; Haverkort HA; de Vries J; Meinardi H
Neuropsychobiology; 1990-1991; 24(2):90-101. PubMed ID: 2134116
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life.
Saletu B; Linzmayer L; Grünberger J; Pietschmann H
Neuropsychobiology; 1985; 13(1-2):44-52. PubMed ID: 3897895
[TBL] [Abstract][Full Text] [Related]
18. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.
Kanowski S; Herrmann WM; Stephan K; Wierich W; Hörr R
Pharmacopsychiatry; 1996 Mar; 29(2):47-56. PubMed ID: 8741021
[TBL] [Abstract][Full Text] [Related]
19. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID.
Saletu B; Anderer P; Fischhof PK; Lorenz H; Barousch R; Böhmer F
Biol Psychiatry; 1992 Oct; 32(8):668-81. PubMed ID: 1457622
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID).
Fischhof PK; Saletu B; Rüther E; Litschauer G; Möslinger-Gehmayr R; Herrmann WM
Neuropsychobiology; 1992; 26(1-2):65-70. PubMed ID: 1475039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
